DDInter1451 DDInter899
A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter&#39;s syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Phenylbutazone {u} (Compound) resembles {v} (Compound) Alverine
Phenylbutazone {u} (Compound) resembles {v} (Compound) Methadone
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGIS
Phenylbutazone {u} (Compound) upregulates {v} (Gene) GPATCH8
Phenylbutazone {u} (Compound) downregulates {v} (Gene) TNIP1
Phenylbutazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Phenylbutazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Phenylbutazone {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Phenylbutazone (Compound) resembles Alverine (Compound)
Phenylbutazone (Compound) resembles Methadone (Compound)
Phenylbutazone (Compound) binds PTGIS (Gene)
Phenylbutazone (Compound) upregulates GPATCH8 (Gene)
Phenylbutazone (Compound) downregulates TNIP1 (Gene)
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Phenylbutazone may lead to a major life threatening interaction when taken with Iohexol